Novo Nordisk stock has given up ground over the past three years, yet broad valuation checks still point to a company that screens as relatively cheap on its current fundamentals. For investors watching the recent pullback, the contrast between weaker returns and a strong value profile is now front of mind.
- The share price is down 49.5% over the past three years, which puts the current valuation story in focus rather than recent performance.
- Competition with Eli Lilly in GLP-1 weight loss drugs and progress in obesity and metabolic pipeline candidates like LX9851 can support sentiment. However, any setback in clinical data or market adoption may weigh heavily on what investors are willing to pay.
- The broader checks lean cheap, with Novo Nordisk screening as undervalued in 5 of 6 valuation tests. This suggests the stock may be priced below what many investors would expect for a large pharmaceutical group.
The issue now is whether Novo Nordisk’s weaker share performance already reflects the key risks, or if the current valuation still leaves room for further downside if expectations reset.
Spot opportunities that echo Novo Nordisk’s mix of weaker recent returns and strong value checks by scanning our hand picked 277 high quality undervalued stocks.Is Novo Nordisk Still Cheap on Earnings?
The P/E multiple suits Novo Nordisk because earnings remain the main anchor for how investors usually price large pharmaceutical stocks. On this measure, Novo Nordisk currently trades on a P/E of 11.2x, compared with an industry average of about 22.0x and a peer group average of 23.4x. That leaves the stock on roughly half the earnings multiple of similar pharmaceutical companies.
The fair P/E ratio implied by broader checks is 24.3x, which is more in line with where large peers trade. Against that benchmark, Novo Nordisk appears undervalued, since the current 11.2x figure sits well below what this framework suggests might be reasonable given its industry, margins, scale and risk profile. Despite intense GLP-1 competition with Eli Lilly keeping attention on product execution, the market is still pricing Novo Nordisk at a sizable discount to both peers and the modelled fair multiple.
On earnings, Novo Nordisk stock appears undervalued, with its P/E multiple sitting well below both peers and the fair value benchmark.
See what the numbers say about this price — find out in our valuation breakdown.
The Novo Nordisk Narrative: What Would Justify Today's Price?
For Novo Nordisk, Simply Wall St Narratives are the link between the current valuation puzzle and the specific future paths that could justify a higher or lower share price, using clear assumptions about growth, margins and earnings. Each narrative ties its number to a concrete view of how Novo Nordisk's growth, profitability and risk profile could evolve, which gives you something structured to revisit as fresh results, trial data and competitive developments emerge on the Community page.
Community views on Novo Nordisk are split, with some investors seeing deep value and others focusing on structural limits to the obesity opportunity.
Bull case: 65% undervalued
"With the unexpected success of its obesity drugs, the company has effectively gained a highly profitable new business segment almost for free..."
Read the full Bull Case to see why Novo Nordisk could be undervalued
Bear case: roughly fairly valued
"Manufacturing capacity is constrained until roughly 2029, limiting volume growth regardless of demand..."
Read the full Bear Case to see why Novo Nordisk could be overvalued
Do you think there's more to the story for Novo Nordisk? Head over to our Community to see what others are saying!
The Bottom Line
For Novo Nordisk, the current market multiples still point to an undervalued stock on earnings compared with large pharmaceutical peers. The broader valuation checks look strong overall, which suggests the discount is more about how investors weigh future GLP-1 competition, capacity constraints, and regulatory or clinical risks than about the existing financial profile.
The key swing factor from here is whether Novo Nordisk can sustain attractive economics in obesity and related treatments without meaningful disappointment on execution or market adoption. That single question will likely decide whether the current discount proves to be an opportunity or a value trap.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com